Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Feb 02, 2019 - NVO earnings call for the period ending December 31, 2018.
Feb 01, 2019 - Novo Nordisk A/S (NYSE:NVO) Q4 2018 Earnings Conference Call February 1, 2019 7:00 AM ET Company Participants Lars Fruergaard Jørgensen – Chief Executive Officer Karsten Munk Knudsen – Chief Financial
Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Nov 08, 2018 - Growth on one hand, but declines on the other.
Nov 01, 2018 -
Nov 01, 2018 - NVO earnings call for the period ending September 30, 2018.
Oct 15, 2018 - PFE vs. NVO: Which Stock Is the Better Value Option?
Sep 19, 2018 - Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.